GNRH1 and dementia: Exclusion of patients in the GnRH agonist and orchiectomy groups who received antiandrogen treatment yielded an increased risk of all-cause dementia (HR, 1.32; 95% CI, 1.14-1.53) and AD (HR, 1.54; 95% CI, 1.14-2.08), which was consistent with the main results (Figure 3).